Improved antitumor activity of cisplatin combined with Ganoderma lucidum polysaccharides in U14 cervical carcinoma-bearing mice

Kaohsiung J Med Sci. 2019 Apr;35(4):222-229. doi: 10.1002/kjm2.12020. Epub 2019 Apr 8.


Research on anticervical cancer is urgently required to enhance clinical outcomes. As a main anticancer drug for cervical carcinoma, cisplatin (CIS) has been used for a lot of years in clinical therapy. However, serious adverse effects including nephrotoxicity and neurotoxicity limit its long-term treatment. Our main goal of this study is to investigate the improvement of Ganoderma lucidum polysaccharides (GPS) on CIS-induced antitumor effect of in U14 cervical carcinoma-bearing mice. The results showed that GPS + CIS could not only inhibit the growth of the tumor but also improve the spleen and thymus indexes. Moreover, little toxicological effects were observed on hepatic function and renal function in GPS + CIS treated mice bearing U14 tumor cells. Further analysis of the tumor inhibition mechanism indicated that the number of apoptotic tumor cells increased significantly, the expression of Bax increased and the expression of Bcl-2 decreased dramatically in cervical cancer sections after oral administration of GPS + CIS for 14 days. This GPS/CIS combined therapy represents intriguing therapeutic strategy for U14 cervical carcinoma providing not only superior efficacy but also a higher safety level.

Keywords: Ganoderma lucidum polysaccharides; cervical carcinoma; cisplatin; combined treatment.

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Aspartate Aminotransferases / blood
  • Blood Urea Nitrogen
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use*
  • Creatinine / blood
  • Female
  • Leukocyte Count
  • Mice
  • Polysaccharides / pharmacology
  • Polysaccharides / therapeutic use*
  • Reishi / chemistry*
  • Survival Analysis
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology
  • Uterine Cervical Neoplasms / blood
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / pathology
  • bcl-2-Associated X Protein / metabolism


  • Antineoplastic Agents
  • Polysaccharides
  • bcl-2-Associated X Protein
  • Creatinine
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Cisplatin